| 000 | 01369 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513213349.0 | ||
| 264 | 0 | _c20000815 | |
| 008 | 200008s 0 0 fre d | ||
| 022 | _a0013-7006 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReggiani, K | |
| 245 | 0 | 0 |
_a[Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism]. _h[electronic resource] |
| 260 |
_bL'Encephale _c |
||
| 300 |
_a62-7 p. _bdigital |
||
| 500 | _aPublication Type: English Abstract; Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntidepressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 |
_aBrain _xphysiology |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression _xgenetics |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMental Disorders _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolymorphism, Genetic _xgenetics |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aVandel, P | |
| 700 | 1 | _aHaffen, E | |
| 700 | 1 | _aSechter, D | |
| 700 | 1 | _aBizouard, P | |
| 700 | 1 | _aVandel, S | |
| 773 | 0 |
_tL'Encephale _gvol. 26 _gno. 1 _gp. 62-7 |
|
| 999 |
_c10825756 _d10825756 |
||